Psychological and quality of life effects of vaccination against COVID-19 in patients with systemic autoimmune diseases

To verify the psychological and quality of life benefits of vaccination against COVID-19 in patients with systemic autoimmune diseases. In this study, levels of psychological stress, psychopathological symptoms, quality of life, and satisfaction with life were compared in patients with systemic autoimmune diseases vaccinated against COVID-19 (n = 132) versus unvaccinated patients (n = 254). To this end, we used the Perceived Stress Scale (PSS), Symptom Checklist-90-Revised (SCL-90-R), EUROQoL-5Q health questionnaire, and Satisfaction with Life Scale (SWLS), respectively. Statistically significant differences were found with better scores in the vaccinated group in the following quality of life dimensions: mobility (p <= 0.010), domestic activities (p <= 0.004), pain/discomfort (p <= 0.001), and anxiety/depression (p <= 0.005). The scores were also significantly higher in the vaccinated group for the total values of quality of life (p <= 0.001), health status self-assessment on the EUROQoL-5Q (p <= 0.043), and satisfaction with life (p <= 0.015). In addition, the unvaccinated group presented higher scores with clinically pathological levels in depression and psychoticism for somatizations (p <= 0.006), depression (p <= 0.015), anxiety (p <= 0.003), and phobic anxiety (p <= 0.001). Finally, participants vaccinated with the complete regimen showed better levels of psychological well-being than those who were not vaccinated or those that had not completed the vaccination regimen. Our results reflect and confirm the positive effects reported elsewhere of the COVID-19 vaccine in autoimmune patients with systemic diseases, both in terms of quality and satisfaction with life as well as psychopathological symptoms and perceived stress. These benefits increased as the patients completed their vaccination schedule.